← Back to Clinical Trials
Recruiting NCT06837844

NCT06837844 Combined Intrathecal Dexmedetomidine and Adductor Canal Block for Analgesia After Total Knee Arthroplasty

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06837844
Status Recruiting
Phase
Sponsor Kafrelsheikh University
Condition Intrathecal Dexmedetomidine
Study Type INTERVENTIONAL
Enrollment 75 participants
Start Date 2025-02-20
Primary Completion 2025-08-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Intrathecal DexmedetomidineAdductor Canal BlockIntrathecal Dexmedetomidine + Adductor Canal Block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 75 participants in total. It began in 2025-02-20 with a primary completion date of 2025-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this work is to evaluate the effect of combined intrathecal dexmedetomidine and adductor canal block for analgesia after total knee arthroplasty (TKA).

Eligibility Criteria

Inclusion Criteria: * Age from 18 to 75 years. * Both sexes. * American Society of Anesthesiology (ASA) physical status I-II. * Scheduled for total knee arthroplasty under spinal anesthesia. Exclusion Criteria: * Patients with neurological or intellectual disability. * History of allergy to local anesthetics or dexmedetomidine . * Infection at the injection site. * Prolonged use of analgesic or sedative medications. * Coagulation abnormalities. * Pregnancy. * Obesity \[body mass index (BMI) \> 30 kg/m2\].

Contact & Investigator

Central Contact

Sherif K Arafa, MD

✉ Sherifhafez1980@gmail.com

📞 00201005714014

Frequently Asked Questions

Who can join the NCT06837844 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Intrathecal Dexmedetomidine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06837844 currently recruiting?

Yes, NCT06837844 is actively recruiting participants. Contact the research team at Sherifhafez1980@gmail.com for enrollment information.

Where is the NCT06837844 trial being conducted?

This trial is being conducted at Kafr ash Shaykh, Egypt.

Who is sponsoring the NCT06837844 clinical trial?

NCT06837844 is sponsored by Kafrelsheikh University. The trial plans to enroll 75 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology